Iteria Biopharma

What Iteria Biopharma does

Iteria Biopharma SL is a privately held Spanish biotech founded in 2024 and headquartered in the Touro Business Park, A Coruña, Galicia, Spain. The company is a spin-off from GalChimia's MAOPROST project, founded by Carme Pampín (CEO of GalChimia), Julio Castro (CEO and founder of Palobiofarma), and Ramon Bosser (CEO), with Ramon Bosser serving as CEO. Its mission is the discovery and development of first-in-class New Chemical Entities (NCEs) targeting challenging oncology indications where existing treatments are inadequate, primarily metastatic castration-resistant prostate cancer and other metastatic solid tumors including pancreatic, colorectal, and lung cancer. The team has a proven exit track record through their prior venture Origo Biopharma, which was acquired by Belgian company Agomab Therapeutics in 2021.

The company's core technology is "smart medicinal chemistry" applied to pharmacologically validated targets that are difficult to modulate through standard drug discovery methods. Its pipeline comprises three assets: ITR-251, an MAO-A inhibitor in IND-enabling/Phase-1 development with Phase 1 clinical trial initiation planned for early 2027 for metastatic castration-resistant prostate cancer; ITR-XXX, a kinase protein degrader program at IND-enabling stage; and ITR-YYY, a nuclear receptor antagonist program in early discovery for metastatic solid tumors. The company protects its candidates with recent product patents and pursues a lean project management approach to early development. The company is led by a multidisciplinary team including CSO Judit Anido (ex-Mosaic Biomedicals, Northern Biologics, Vall d'Hebron), Head of Chemistry Raúl Fernández (ex-GalChimia), Business Development Director Luis Ruiz-Ávila, and Clinical Project Manager Cristina López (ex-Novartis).

Iteria is pre-revenue with no commercial products and no disclosed pricing. The business model is the standard biotech development-and-exit pathway: progress novel NCEs through preclinical and clinical development with the intent of out-licensing, partnership, or eventual commercialization through a pharmaceutical partner. To date the company has been financed by a €5 million Series Seed round (April 2026) led by Inveready (Inveready Biotech IV) with co-investment from Xesgalicia (Xunta de Galicia's VC arm) and the founding partners, supplemented by non-dilutive grants from Spain's CDTI NEOTEC program (SNEO-20251130) and the Agencia Estatal de Investigación Public-Private Partnership program (CPP2024-011416 ONCOMAO). Headcount is reported at 1–10 employees per firmographics, with named team members spanning scientific, operational, and business development functions.

Name

Iteria Biopharma

Legal name

Iteria Biopharma SL

Website

https://iteriabiopharma.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

Iteria Biopharma is a privately held Spanish biotech founded in 2024, developing first-in-class small-molecule oncology drugs — led by MAO-A inhibitor ITR-251 for metastatic castration-resistant prostate cancer — using smart medicinal chemistry against challenging targets for patients with high unmet medical need.

Ownership category

akta.pro rank

Product category

Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Oncology Specialty Pharmaceuticals (HLAIACAA)

akta.pro secondary industries

Oncology & Hematology Pharmaceuticals (HLAIAAAC), Translational Medicine & Biomarkers (HLAIALAF)

Keywords

• Oncology drug discovery
• Cancer therapeutics
• Medicinal chemistry
• Preclinical biotech
• New chemical entities

Headquarters

HQ city

Touro

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations

Marketing channels3 records

Core offering

Iteria Biopharma discovers and develops first-in-class New Chemical Entities (NCEs) for the treatment of advanced metastatic cancers, with a primary focus on metastatic castration-resistant prostate cancer. The company applies smart medicinal chemistry to pharmacologically validated oncology targets that are difficult to modulate through standard drug discovery methods. Its pipeline currently includes ITR-251 (MAO-A inhibitor), a kinase protein degrader program, and a nuclear receptor antagonist program.

Product overview

Iteria Biopharma is a privately owned Spanish biotech company founded in 2024, focused on the discovery and development of innovative drugs for the treatment of advanced metastatic cancers. The company operates a pipeline of three drug candidates: ITR-251 (MAO-A inhibitor for metastatic castration-resistant prostate cancer, in IND-enabling/Phase-1), ITR-XXX (kinase protein degrader in IND-enabling stage), and ITR-YYY (nuclear receptor antagonist for metastatic solid tumors in discovery stage). The company leverages smart medicinal chemistry approaches to modulate challenging targets that are difficult to address using conventional drug discovery methods.

Differentiator

Problem solved

Functional benefit

Products and services

• ITR-251 ITR-251 is a first-in-class MAO-A inhibitor drug candidate in development for the treatment of solid tumors, with a primary focus on metastatic castration-resistant prostate cancer. The compound is in IND-enabling/Phase-1 stage, with a Phase 1 clinical trial planned for early 2027. It targets MAO-A inhibition as a novel mechanism to address castration-resistant prostate cancer, a setting where existing drugs lose efficacy and the 5-year survival rate for metastatic disease is 38%.
• ITR-XXX (Kinase Protein Degrader Program) ITR-XXX is an early-stage kinase protein degrader program in IND-enabling stage, targeting cancers with high unmet medical need. The program applies targeted protein degradation to kinase targets as a novel therapeutic modality for cancer treatment.
• ITR-YYY (Nuclear Receptor Antagonist Program) ITR-YYY is a nuclear receptor antagonist program in early discovery stage for the treatment of metastatic solid tumors, including pancreatic, colorectal, and lung cancer indications where there is high unmet medical need.

Quantifiable outcome

• 38% 5-year survival rate for metastatic prostate cancer - Iteria aims to improve outcomes for these patients with high unmet need

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• GalChimiacoreStrategic or Co-development Partner · 1 January 2024One of the three founding partners of Iteria Biopharma. GalChimia is a Spanish CRO led by Carme Pampín, specialized in chemistry services for the pharmaceutical industry. The company originated the MAOPROST project that Iteria is now developing. Carme Pampín serves as Co-Founder of Iteria.
• Julio Castro (Palobiofarma)coreStrategic or Co-development Partner · 1 January 2024One of the three founding partners of Iteria Biopharma. Julio Castro is CEO and founder of Palobiofarma with sites in Navarra and Barcelona, bringing over 25 years of experience in drug discovery and development. Previously involved in the successful Origo Biopharma venture.
• Ramon BossercoreStrategic or Co-development Partner · 1 January 2024Co-Founder and CEO of Iteria Biopharma with more than 28 years of experience in pharma and biotech R&D. Previously CEO of Origo Biopharma which was acquired by Agomab Therapeutics. Brings extensive drug development program experience from Almirall and Spherium Biomed.
• Agomab TherapeuticsminorOthers · 1 January 2021Belgian company that acquired Origo Biopharma in 2021, continuing clinical development of programs initiated by Origo including candidates for fibrostenosis associated with Crohn's disease and idiopathic pulmonary fibrosis. Not a current Iteria partner but noted as previous success of the founding team.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Emerging players

• Kymera Therapeutics: Clinical-stage biotech developing small-molecule protein degraders for oncology and immunology. Highly comparable to Iteria's kinase protein degrader platform (ITR-XXX) through shared technology approach and oncology focus.
• Foghorn Therapeutics: Clinical-stage biotech developing medicines targeting chromatin biology and nuclear receptor dysregulation in cancer. Directly comparable to Iteria's nuclear receptor antagonist program (ITR-YYY) through shared mechanism class and oncology focus.
• Nuage Therapeutics: Spanish biotech focused on protein-protein interaction drug discovery, previously led by Iteria's CSO Judit Anido. Closely linked to Iteria through management overlap and shared focus on challenging-to-drug targets via novel chemistry approaches.

Broad incumbents

• Arvinas: Pioneer and clinical-stage leader in targeted protein degradation (PROTAC) technology for oncology, with multiple partnered programs. Directly comparable to Iteria's kinase protein degrader program (ITR-XXX) and provides a benchmark for the protein degradation category.
• PharmaMar: Major publicly-traded Spanish biopharmaceutical company focused on oncology with multiple marketed products (Yondelis, Zepzelca). Provides the benchmark for what successful Spanish oncology drug development looks like at scale, though at a much later stage than Iteria.
• Agomab Therapeutics: Belgian clinical-stage biotech that acquired Origo Biopharma (Iteria founders' previous company) in 2021. Directly connected to Iteria through founder lineage and validates the founders' ability to create exit value.

Direct peers

• Medibiofarma: Spanish biotech previously co-founded by Julio Castro focused on small-molecule drug discovery. Comparable to Iteria in geography and entrepreneurial model, with shared leadership lineage through common founder.
• Leukos Biotech: Spanish biotech developing a Phase I/II oncology product, led by Luis Ruiz-Ávila who also serves as Iteria's Business Development Director. Direct management linkage and similar small-Spanish-oncology profile make this a strong direct peer.
• Palobiofarma: Spanish biotech founded by Iteria's co-founder Julio Castro, focused on discovery and development of novel medicines in oncology. Shares therapeutic focus (NCEs for cancer), business model, and stage profile with Iteria, with deep management DNA overlap through common co-founder.
• Oncostellae: Spanish oncology biotech co-founded by Julio Castro (Iteria co-founder). Similar size, geography, and focus on novel oncology drug discovery. Sara Secall (Inveready, on Iteria's board) also serves on Oncostellae's board, evidencing tight ecosystem linkages.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Iteria Biopharma